The era of personalized medicine: back to basics.
作者信息
Hutchinson Lisa, DeVita Vincent T
出版信息
Nat Clin Pract Oncol. 2008 Nov;5(11):623. doi: 10.1038/ncponc1253.
PMID:18957968
Abstract
摘要
相似文献
1
The era of personalized medicine: back to basics.个性化医疗时代：回归基础。
Nat Clin Pract Oncol. 2008 Nov;5(11):623. doi: 10.1038/ncponc1253.
2
Bcr-abl positive blast crisis of chronic myeloid leukemia emerging in a case of metastatic colorectal cancer 3 months after completion of an 8-month course of cetuximab and irinotecan.
Eur J Haematol. 2006 May;76(5):447-8. doi: 10.1111/j.1600-0609.2006.00630.x. Epub 2006 Feb 23.
3
STI-571 in chronic myelogenous leukaemia.STI-571治疗慢性粒细胞白血病
Br J Haematol. 2002 Oct;119(1):15-24. doi: 10.1046/j.1365-2141.2002.03899.x.
4
Outpacing cancer.
Nat Med. 2009 Jul;15(7):718-22. doi: 10.1038/nm0709-718.
5
Recent advances of molecular targeted agents: opportunities for imaging.分子靶向药物的最新进展：成像机遇
Cancer Biol Ther. 2003 Nov-Dec;2(6):601-9.
6
[Tyrosine kinase inhibitors for the treatment of CML].用于治疗慢性粒细胞白血病的酪氨酸激酶抑制剂
Ther Umsch. 2006 Apr;63(4):249-54. doi: 10.1024/0040-5930.63.4.249.
7
STI571 revolution: can the newer targeted drugs measure up?
J Natl Cancer Inst. 2001 Jul 4;93(13):970-3. doi: 10.1093/jnci/93.13.970.
8
Imatinib for chronic myeloid leukaemia: a NICE mess.伊马替尼用于慢性髓性白血病：英国国家卫生与临床优化研究所的一团糟。
Lancet. 2001 Dec 1;358(9296):1902. doi: 10.1016/S0140-6736(01)06901-X.
9
Cancer treatment. New drugs, new hope.癌症治疗。新药，新希望。
Harv Health Lett. 2001 Jul;26(9):1-3.
10
[Attentive questions about treatment of chronic myelogenous leukemia with imatinib mesylate].
Zhonghua Xue Ye Xue Za Zhi. 2006 Jul;27(7):433-5.
引用本文的文献
1
Minimal residual disease in acute myeloid leukaemia.急性髓系白血病的微小残留病。
Nat Rev Clin Oncol. 2013 Aug;10(8):460-71. doi: 10.1038/nrclinonc.2013.100. Epub 2013 Jun 25.
2
Tailoring tyrosine kinase inhibitors to fit the lung cancer genome.针对肺癌基因组定制酪氨酸激酶抑制剂。
Transl Oncol. 2011 Apr 1;4(2):59-70. doi: 10.1593/tlo.10241.
Zotero 插件